PC
MCID: PRS040
MIFTS: 90

Prostate Cancer (PC) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer

Aliases & Descriptions for Prostate Cancer:

Name: Prostate Cancer 54 38 12 24 25 66 13 52 41 3 14
Prostate Carcinoma 12 24 25 52 14 69
Prostate Cancer, Familial 54 12 50 69
Familial Prostate Cancer 50 56 29
Prostatic Cancer 12 25 14
Malignant Neoplasm of the Prostate 25 29
Malignant Tumor of the Prostate 12 29
Prostate Cancer, Hereditary, 5 54 13
Prostate Cancer, Hereditary 54 50
Hereditary Prostate Cancer 12 50
Prostatic Neoplasms 42 69
Prostatic Neoplasm 12 25
Prostate Neoplasm 12 25
Prostate Cancer, Progression of 54
Malignant Neoplasm of Prostate 69
Ngp - New Growth of Prostate 12
Prostate Cancer, Somatic 54
Prostate Cancer Somatic 54
Cancer of the Prostate 25
Tumor of the Prostate 12
Carcinoma of Prostate 12
Prostatic Carcinoma 25
Cancer of Prostate 12
Prostate Cancer 4 54
Prostate Cancer 3 54
Prca 66
Pc 66

Characteristics:

Orphanet epidemiological data:

56
familial prostate cancer
Prevalence: 1-9/100000 (United States); Age of onset: Adult;

HPO:

32
prostate cancer:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare urogenital diseases


External Ids:

OMIM 54 176807
Disease Ontology 12 DOID:10283 DOID:10286
ICD10 33 C61
ICD9CM 35 185
MeSH 42 D011471
Orphanet 56 ORPHA1331
MESH via Orphanet 43 C537243
UMLS via Orphanet 70 C2931456
ICD10 via Orphanet 34 C61
MedGen 40 C0376358

Summaries for Prostate Cancer

MedlinePlus : 41 the prostate is the gland below a man's bladder that produces fluid for semen. prostate cancer is common among older men. it is rare in men younger than 40. risk factors for developing prostate cancer include being over 65 years of age, family history, and being african-american. symptoms of prostate cancer may include problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling low back pain pain with ejaculation to diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. you may also get a blood test for prostate-specific antigen (psa). these tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. if your results are abnormal, you may need more tests, such as an ultrasound, mri, or biopsy. treatment often depends on the stage of the cancer. how fast the cancer grows and how different it is from surrounding tissue helps determine the stage. men with prostate cancer have many treatment options. the treatment that's best for one man may not be best for another. the options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. you may have a combination of treatments. nih: national cancer institute

MalaCards based summary : Prostate Cancer, also known as prostate carcinoma, is related to prostate cancer 1 and prostate cancer, hereditary, 2, and has symptoms including angina pectoris, tremor and equilibration disorder. An important gene associated with Prostate Cancer is MXI1 (MAX Interactor 1, Dimerization Protein), and among its related pathways/superpathways are Prostate cancer and Glioma. The drugs Degarelix and Eligard have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and breast, and related phenotypes are cellular and endocrine/exocrine gland

Disease Ontology : 12 A male reproductive organ cancer that is located in the prostate.

Genetics Home Reference : 25 Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.

NIH Rare Diseases : 50 familial prostate cancer is a cluster of prostate cancer within a family. most cases of prostate cancer occur sporadically in people with no family history of the condition. however, approximately 5% to 10% of prostate cancer cases are believed to be primarily caused by a genetic predisposition to the condition. in many families, the underlying genetic cause is unknown; however, some of these cases are caused by changes (mutations) in the brca1, brca2, hoxb13, or several other genes. other cases are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.high-risk cancer screening at an earlier age is typically recommended in men who have an increased risk for prostate cancer based on personal and/or family histories. last updated: 12/7/2015

CDC : 3 Prostate cancer is the most common non-skin cancer among American men. Prostate cancers usually grow slowly. Most men with prostate cancer are older than 65 years and do not die from the disease. Finding and treating prostate cancer before symptoms occur may not improve your health or help you live longer.

Novus Biologicals : 53 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

UniProtKB/Swiss-Prot : 66 Prostate cancer: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

Wikipedia : 71 Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system.... more...

Description from OMIM: 176807

Related Diseases for Prostate Cancer

Diseases in the Prostate Cancer family:

Prostate Cancer 1 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 13
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 7
Prostate Cancer, Hereditary, 2 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 9 Prostate Cancer, Hereditary, 15
Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 284)
id Related Disease Score Top Affiliating Genes
1 prostate cancer 1 12.3
2 prostate cancer, hereditary, 2 12.2
3 prostate cancer, hereditary, 13 12.2
4 prostate cancer, hereditary, 11 12.2
5 prostate cancer, hereditary, 12 12.2
6 adenosquamous prostate carcinoma 12.1
7 prostate cancer susceptibility 12.0
8 prostate cancer, hereditary, x-linked 1 11.8
9 prostate cancer, hereditary, 7 11.8
10 prostate cancer/brain cancer susceptibility, somatic 11.8
11 prostate cancer, progression and metastasis of 11.8
12 prostate cancer, hereditary, 9 11.8
13 prostate cancer, hereditary, 10 11.8
14 prostate cancer, hereditary, 15 11.8
15 prostate cancer, hereditary, 14 11.8
16 prostate cancer, hereditary, x-linked 2 11.8
17 prostate carcinoma in situ 11.8
18 prostatitis 11.5
19 prostate disease 11.2
20 radiation proctitis 11.1
21 prostate squamous cell carcinoma 11.0
22 prostate small cell carcinoma 11.0
23 benign prostate phyllodes tumor 10.9
24 prostate neuroendocrine neoplasm 10.9
25 prostate malignant phyllodes tumor 10.9
26 split-hand/foot malformation with long bone deficiency 1 10.9 AR BRCA2 CD82 CDH1 CHEK2 ELAC2
27 diethylstilbestrol syndrome 10.8
28 prostate sarcoma 10.8
29 brca1 hereditary breast and ovarian cancer syndrome 10.8
30 brca2 hereditary breast and ovarian cancer syndrome 10.8
31 adult medulloblastoma 10.7 AR CDH1 ELAC2 FOLH1 HOXB13 KLK3
32 rapsn-related fetal akinesia deformation sequence 10.7 AR BRCA2 CDH1 CHEK2 ELAC2 HOXB13
33 bardet-biedl syndrome 10.6 AR BRCA2 CDH1 FOLH1 KLK3 PTEN
34 skin hemangioma 10.6 AR FOLH1 KLK3 SRD5A2
35 splenic infarction 10.6 AR FOLH1 KLK3 PTEN
36 endotheliitis 10.5
37 nevoid hypermelanosis, linear and whorled 10.5 BRCA2 CDH1 KLK3 PTEN
38 bronchogenic cyst 10.5 BRCA2 CHEK2 PTEN
39 bronchiectasis oligospermia 10.5 BRCA2 CHEK2 PTEN
40 polyembryoma of the ovary 10.5 BRCA2 CHEK2 PTEN
41 congenital bile acid synthesis defect 10.5 AR BRCA2 KLK3
42 larynx liposarcoma 10.5 BRCA2 CHEK2 PTEN
43 pituitary stalk meningioma 10.4 BRCA2 CHEK2 PTEN
44 hypoxia 10.4
45 hole retinal cyst 10.4 AR KLK3
46 nasopharyngeal carcinoma 10.4 BRCA2 CHEK2 PTEN
47 insulin-like growth factor i 10.4
48 trachea squamous cell carcinoma 10.3 BRCA2 CDH1 PTEN
49 breast cancer 10.2
50 leukemia 10.2

Comorbidity relations with Prostate Cancer via Phenotypic Disease Network (PDN): (show all 35)


Acute Kidney Failure Anthracosis
Asbestosis Azoospermia
Balanoposthitis Bladder Neck Obstruction
Chronic Kidney Failure Cystitis Cystica
Deficiency Anemia Disseminated Intravascular Coagulation
Epididymo-Orchitis Gout
Hydronephrosis Kidney Disease
Lipoma of Spermatic Cord Lymphadenitis
Nephrolithiasis, Type I Paralytic Ileus
Paraplegia Prostate Calculus
Prostate Carcinoma in Situ Prostate Disease
Prostatic Hypertrophy Prostatitis
Radiation Cystitis Spermatocele
Spinal Cord Disease Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Bladder Cancer Urinary Tract Obstruction
Y Chromosome Infertility

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to Prostate Cancer

Symptoms & Phenotypes for Prostate Cancer

Symptoms by clinical synopsis from OMIM:

176807

Clinical features from OMIM:

176807

Human phenotypes related to Prostate Cancer:

32
id Description HPO Frequency HPO Source Accession
1 prostate cancer 32 HP:0012125

UMLS symptoms related to Prostate Cancer:


angina pectoris, tremor, equilibration disorder

MGI Mouse Phenotypes related to Prostate Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 KLF6 MAD1L1 MXI1 POLK PTEN RNASEL
2 endocrine/exocrine gland MP:0005379 10.03 AR BRCA2 CDH1 CHEK2 EPHB2 HOXB13
3 mortality/aging MP:0010768 9.97 AR BRCA2 CDH1 CHEK2 ELAC2 EPHB2
4 neoplasm MP:0002006 9.65 BRCA2 CD82 CDH1 CHEK2 FGFR4 MAD1L1
5 reproductive system MP:0005389 9.36 AR BRCA2 CDH1 EPHB2 FGFR4 HOXB13

Drugs & Therapeutics for Prostate Cancer

FDA approved drugs:

(show all 17)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Degarelix 17 46 degarelix Ferring Pharmaceuticals Approved December of 2008
2
Eligard 17 46 LEUPROLIDE ACETATE Atrix Laboratories Approved January 2002
3
Eulexin 17 FLUTAMIDE Schering-Plough Approved June 1996
4
Iressa 17 46 GEFITINIB AstraZeneca Approved May 2003
5
Jevtana 17 46 CABAZITAXEL sanofi aventis Approved June 2010
6
Lupron Depot 17 46 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories Approved July 1997/ Approved January 1996
7
Plenaxis 17 ABARELIX Praecis Pharmaceuticals Approved December 2003
8
Provenge 17 46 sipuleucel-T Dendreon Approved May 2010
9
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer Approved May 1996
10
Trelstar Depot/ Trelstar LA 17 TRIPTORELIN PAMOATE Debio Rechereche Pharmaceutique, Target Research Associates/ Debiopharm Approved June 2000/ Approved June 2001
11
Viadur 17 46 LEUPROLIDE ACETATE Alza Approved March 2000
12
Xgeva 17 46 DENOSUMAB Amgen Approved June 2013/ Approved November 2010
13
Xofigo 17 46 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals Approved May 2013
14
Xtandi 17 46 ENZALUTAMIDE Medivation Approved August 2012
15
Zoladex 17 46 GOSERELIN ACETATE AstraZeneca Approved January 1996
16
Zometa 17 46 ZOLEDRONIC ACID Novartis Approved August 2001/ Approved February 2002
17
Zytiga 17 46 ABIRATERONE ACETATE Centocor Ortho Biotech Approved May 2011

Drugs for Prostate Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 864)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1 65807-02-5 47725 5311128
2
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53714-56-0 3911 657181
3
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 164656-23-9 152945 6918296
4
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
6
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
7
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
10
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90357-06-5 56069 2375
11
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
12
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
13
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
14
Ciprofloxacin Approved, Investigational Phase 4,Phase 2 85721-33-1 2764
15
Benzocaine Approved Phase 4,Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
16
Ropivacaine Approved Phase 4,Phase 3 84057-95-4 71273 175805
17
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
18
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
19
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
20
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
21
Flutamide Approved Phase 4,Phase 3,Phase 2,Phase 1 13311-84-7 3397
22
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
23 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7681-49-4
24
Tamsulosin Approved, Investigational Phase 4,Phase 3 106133-20-4 129211
25
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6 772 46507594
26
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
27
Finasteride Approved Phase 4,Phase 3,Phase 2 98319-26-7 57363
28
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
29
Diphenhydramine Approved Phase 4,Phase 2,Phase 1 58-73-1, 147-24-0 3100
30
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
31
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
32
Ondansetron Approved Phase 4 99614-02-5 4595
33
Promethazine Approved Phase 4,Phase 2,Phase 1 60-87-7 4927
34
Ranitidine Approved Phase 4,Phase 2 66357-59-3, 66357-35-5 3001055
35
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
36
Desflurane Approved Phase 4 57041-67-5 42113
37
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
38
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
39
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
40
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
41
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
42
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
43
Hydromorphone Approved, Illicit Phase 4,Phase 3 466-99-9 5284570
44
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
45
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 9004-61-9 53477741 24759
46
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3 104987-11-3 445643 439492
47
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1 171596-29-5 110635
48
Prilocaine Approved Phase 4 721-50-6 4906
49
Fibrinolysin Approved Phase 4 9004-09-5
50
Tranexamic Acid Approved Phase 4 1197-18-8 5526

Interventional clinical trials:

(show top 50) (show all 3944)
id Name Status NCT ID Phase
1 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4
2 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
3 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
4 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
5 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4
6 Early Detection of Prostate Cancer by FACS Unknown status NCT00524823 Phase 4
7 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
8 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine. Completed NCT01302054 Phase 4
9 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer Completed NCT00199485 Phase 4
10 Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer Completed NCT01511874 Phase 4
11 Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Completed NCT00363311 Phase 4
12 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4
13 Docetaxel in the Treatment of Hormone Refractory Prostate Cancer Completed NCT00280098 Phase 4
14 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4
15 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4
16 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4
17 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy Completed NCT00237146 Phase 4
18 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4
19 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4
20 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed NCT01296672 Phase 4
21 An Alternative to A Fixed Schedule In Management Of Prostate Cancer Completed NCT01056562 Phase 4
22 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4
23 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4
24 Casodex/Zoladex Biomarkers in Localised Prostate Cancer Completed NCT00293696 Phase 4
25 Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Completed NCT00805701 Phase 4
26 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4
27 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4
28 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4
29 Study to Monitor the Effects of Androgen Suppression Treatment on the Heart Completed NCT01230905 Phase 4
30 Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Completed NCT00590213 Phase 4
31 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4
32 The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4
33 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4
34 Evaluate Recovery of Testosterone for Patients Using Eligard Completed NCT01136226 Phase 4
35 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4
36 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4
37 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer Completed NCT00859027 Phase 4
38 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Completed NCT00470834 Phase 4
39 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy Completed NCT00245518 Phase 4
40 Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases Completed NCT00434317 Phase 4
41 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4
42 Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer Completed NCT00953277 Phase 4
43 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4
44 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed NCT01083199 Phase 4
45 Local Anesthesia for Prostate Biopsy Completed NCT00422708 Phase 4
46 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
47 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide Completed NCT02149628 Phase 4
48 The Use of Thermal Suits as Preventing Hypothermia During Surgery Completed NCT01571544 Phase 4
49 The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function Completed NCT01547416 Phase 4
50 Hydroxyethyl Starch and Renal Function After Radical Prostatectomy Completed NCT01486563 Phase 4

Search NIH Clinical Center for Prostate Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Prostate Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Prostate Cancer:
Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers

Cochrane evidence based reviews: prostatic neoplasms

Genetic Tests for Prostate Cancer

Genetic tests related to Prostate Cancer:

id Genetic test Affiliating Genes
1 Malignant Tumor of Prostate 29
2 Familial Prostate Cancer 29
3 Prostate Cancer 29 24 RNASEL CHEK2
4 Prostate Neoplasm 29

Anatomical Context for Prostate Cancer

MalaCards organs/tissues related to Prostate Cancer:

39
Prostate, Bone, Breast, Endothelial, Lymph Node, Testes, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Prostate Cancer:

18
The Prostate

Publications for Prostate Cancer

Articles related to Prostate Cancer:

(show top 50) (show all 13006)
id Title Authors Year
1
Signaling networks in TMPRSS2-ERG positive prostate cancers: Do we need a Pied Piper or sharpshooter to deal with "at large" fused oncoprotein. ( 28364793 )
2017
2
Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. ( 28004109 )
2017
3
Prognostic value of endocan in prostate cancer: clinicopathologic association between serum endocan levels and biochemical recurrence after radical prostatectomy. ( 27470607 )
2017
4
Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer. ( 28086825 )
2017
5
Repeatability of [(68)Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. ( 28534214 )
2017
6
miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression. ( 27878260 )
2017
7
Atorvastatin prolongs the lifespan of radiationa89induced reactive oxygen species in PC-3 prostate cancer cells to enhance the cell killing effect. ( 28260074 )
2017
8
Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection. ( 28089303 )
2017
9
Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology. ( 28089387 )
2017
10
TIMP4 expression is regulated by miR-200b-3p in prostate cancer cells. ( 28028835 )
2017
11
Knockdown of FOXR2 suppresses the tumorigenesis, growth and metastasis of prostate cancer. ( 28068638 )
2017
12
miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. ( 28122308 )
2017
13
Downregulation of Rab23 in Prostate Cancer Inhibits Tumor Growth In Vitro and In Vivo. ( 28277196 )
2017
14
High-Level I^-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. ( 28146062 )
2017
15
MicroRNA-590-3p promotes cell proliferation and invasion by targeting inositol polyphosphate 4-phosphatase type II in human prostate cancer cells. ( 28345464 )
2017
16
Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. ( 28532278 )
2017
17
Editorial Comment to Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology. ( 28087898 )
2017
18
Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy. ( 26780868 )
2017
19
Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer. ( 27278788 )
2017
20
Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer. ( 28011482 )
2017
21
Meta-analysis of the role of IL-6 rs1800795 polymorphism in the susceptibility to prostate cancer: Evidence based on 17 studies. ( 28296724 )
2017
22
Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. ( 28089304 )
2017
23
MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein. ( 27959429 )
2017
24
Inhibition of cell survival and proliferation by nimbolide in human androgen-independent prostate cancer (PC-3) cells: involvement of the PI3K/Akt pathway. ( 28025797 )
2017
25
Prostate-specific membrane antigen-directed nanoparticle targeting for extreme nearfield ablation of prostate cancer cells. ( 28351335 )
2017
26
Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). ( 28532400 )
2017
27
Ninjurin1 Is Up-regulated in Circulating Prostate Tumor Cells and Plays a Critical Role in Prostate Cancer Cell Motility. ( 28373430 )
2017
28
Cripto-1 promotes epithelial-mesenchymal transition in prostate cancer via Wnt/I^-catenin signaling. ( 28098905 )
2017
29
Synthesis and evaluation of [(64)Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer. ( 28533936 )
2017
30
Reply from Authors re: Jens Uwe Stolzenburg, Iason Kyriazis, Evangelos Liatsikos. Postoperative Lymphocele Formation after Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy Should Not Be Considered an Inevitable Consequence of the Approach. Eur Urol 2017;71:159-60: Which Lymphatic Vessels Have To Be Secured During Pelvic Lymph Node Dissection for Prostate Cancer? ( 27666998 )
2017
31
Androgen Mediated Regulation of Endoplasmic Reticulum-Associated Degradation and its Effects on Prostate Cancer. ( 28091582 )
2017
32
miRNA-154-5p Inhibits Proliferation, Migration and Invasion by Targeting E2F5 in Prostate Cancer Cell Lines. ( 27074041 )
2017
33
Serotonin receptor 4 (5-hydroxytryptamine receptor Type 4) regulates expression of estrogen receptor beta and cell migration in hormone-naive prostate cancer. ( 28195088 )
2017
34
Changes in the Level of Circulating hsa-miR-297 and hsa-miR-19b-3p miRNA Are Associated with Generalization of Prostate Cancer. ( 28091918 )
2017
35
miR-101 Enhances Cisplatin-Induced DNA Damage Through Decreasing Nicotinamide Adenine Dinucleotide Phosphate Levels by Directly Repressing Tp53-Induced Glycolysis and Apoptosis Regulator Expression in Prostate Cancer Cells. ( 28384067 )
2017
36
RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells. ( 28257035 )
2017
37
Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1, c-Myc, cyclinA D1 and MMP-7. ( 27922675 )
2017
38
Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. ( 27358489 )
2017
39
Correction for Dash et al., Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. ( 28533399 )
2017
40
Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men. ( 28353585 )
2017
41
Regulation of Docetaxel Sensitivity in Prostate Cancer Cells by Hsa-miR-125A-3P via Modulation of MTA1 Signaling. ( 28088556 )
2017
42
Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer. ( 27983526 )
2017
43
TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. ( 28533357 )
2017
44
The ubiquitin ligase UBE4A inhibits prostate cancer progression by targeting interleukin-like EMT inducer (ILEI). ( 27862841 )
2017
45
Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer. ( 28073170 )
2017
46
Single-nucleotide polymorphism rs1058205 of KLK3 is associated with the risk of prostate cancer: A case-control study of Han Chinese men in Northeast China. ( 28272245 )
2017
47
Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro. ( 28008585 )
2017
48
Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy. ( 28534538 )
2017
49
Silencing CAPN2 Expression Inhibited Castration-Resistant Prostate Cancer Cells Proliferation and Invasion via AKT/mTOR Signal Pathway. ( 28280729 )
2017
50
Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. ( 27643404 )
2017